Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L (2017) Crohn’s disease. Lancet 389(10080):1741–1755. https://doi.org/10.1016/S0140-6736(16)31711-1

Article  PubMed  Google Scholar 

Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ (2010) The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol 105(2):289–297. https://doi.org/10.1038/ajg.2009.579

Article  PubMed  Google Scholar 

Leal RF, Planell N, Kajekar R, Lozano JJ, Ordas I, Dotti I, Esteller M, Masamunt MC, Parmar H, Ricart E, Panes J, Salas A (2015) Identification of inflammatory mediators in patients with Crohn’s disease unresponsive to anti-TNFalpha therapy. Gut 64(2):233–242. https://doi.org/10.1136/gutjnl-2013-306518

Article  CAS  PubMed  Google Scholar 

Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, Gonzalez-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G (2020) ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 14(1):4–22. https://doi.org/10.1093/ecco-jcc/jjz180

Article  PubMed  Google Scholar 

Cushing K, Higgins PDR (2021) Management of Crohn disease: a review. JAMA 325(1):69–80. https://doi.org/10.1001/jama.2020.18936

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh S, Fumery M, Sandborn WJ, Murad MH (2018) Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn’s disease. Aliment Pharmacol Ther 48(4):394–409. https://doi.org/10.1111/apt.14852

Article  CAS  PubMed  Google Scholar 

Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A, Van der Woude J, Baert F, Eliakim R, Katsanos K, Brynskov J, Steinwurz F, Danese S, Vermeire S, Teillaud JL, Lemann M, Chowers Y (2010) Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 4(4):355–366. https://doi.org/10.1016/j.crohns.2010.04.004

Article  PubMed  Google Scholar 

Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Scholmerich J, Panes J, Sandborn WJ, Investigators PRS (2010) Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 105(7):1574–1582. https://doi.org/10.1038/ajg.2010.78

Article  CAS  PubMed  Google Scholar 

Gisbert JP, Panes J (2009) Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 104(3):760–767. https://doi.org/10.1038/ajg.2008.88

Article  CAS  PubMed  Google Scholar 

Li L, Chen R, Zhang Y, Zhou G, Chen B, Zeng Z, Chen M, Zhang S (2021) A novel model based on serum biomarkers to predict primary non-response to infliximab in Crohn’s disease. Front Immunol 12:646673. https://doi.org/10.3389/fimmu.2021.646673

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zapater P, Almenara S, Gutierrez A, Sempere L, Garcia M, Laveda R, Martinez A, Scharl M, Cameo JI, Linares R, Gonzalez-Navajas JM, Wiest R, Rogler G, Frances R (2019) Actual anti-TNF trough levels relate to serum IL-10 in drug-responding patients with Crohn’s disease. Inflamm Bowel Dis 25(8):1357–1366. https://doi.org/10.1093/ibd/izz012

Article  PubMed  Google Scholar 

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T, Group UKIBDPS (2019) Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 4(5):341–353. https://doi.org/10.1016/S2468-1253(19)30012-3

Article  PubMed  Google Scholar 

Gisbert JP, Chaparro M (2020) Predictors of primary response to biologic treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis 14(5):694–709. https://doi.org/10.1093/ecco-jcc/jjz195

Article  PubMed  Google Scholar 

Bruining DH, Zimmermann EM, Loftus EV Jr, Sandborn WJ, Sauer CG, Strong SA, Society of Abdominal Radiology Crohn’s Disease-Focused P (2018) Consensus recommendations for evaluation, interpretation, and utilization of computed tomography and magnetic resonance enterography in patients with small bowel Crohn’s disease. Radiology 286(3):776–799. https://doi.org/10.1148/radiol.2018171737

Article  PubMed  Google Scholar 

Ognibene NM, Basile M, Di Maurizio M, Petrillo G, De Filippi C (2016) Features and perspectives of MR enterography for pediatric Crohn disease assessment. Radiol Med 121(5):362–377. https://doi.org/10.1007/s11547-015-0613-2

Article  PubMed  Google Scholar 

Cicero G, Alibrandi A, Blandino A, Ascenti V, Fries W, Viola A, Mazziotti S (2023) DWI ratios: New indexes for Crohn’s disease activity at magnetic resonance enterography? Radiol Med (Torino) 128(1):16–26. https://doi.org/10.1007/s11547-022-01573-7

Article  PubMed  Google Scholar 

Napolitano M, Munari AM, Di Leo G, Panarisi NAR, Zuin G, Fava G, Vecchi M, Sardanelli F, Zuccotti GV (2021) MR enterography grading of pediatric ileocolonic Crohn disease activity based on a single bowel segment. Radiol Med (Torino) 126(11):1396–1406. https://doi.org/10.1007/s11547-021-01409-w

Article  PubMed  Google Scholar 

Rimola J, Torres J, Kumar S, Taylor SA, Kucharzik T (2022) Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. Gut 71(12):2587–2597. https://doi.org/10.1136/gutjnl-2021-326562

Article  PubMed  Google Scholar 

Baker ME, Hara AK, Platt JF, Maglinte DD, Fletcher JG (2015) CT enterography for Crohn’s disease: optimal technique and imaging issues. Abdom Imaging 40(5):938–952. https://doi.org/10.1007/s00261-015-0357-4

Article  PubMed  Google Scholar 

Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, Zegers CML, Gillies R, Boellard R, Dekker A, Aerts HJWL (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48(4):441–446. https://doi.org/10.1016/j.ejca.2011.11.036

Article  PubMed  PubMed Central  Google Scholar 

Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures. They Are Data Radiology 278(2):563–577. https://doi.org/10.1148/radiol.2015151169

Article  PubMed  Google Scholar 

Zhu C, Hu J, Wang X, Li C, Gao Y, Li J, Ge Y, Wu X (2022) A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn’s disease patients treated with infliximab. Eur Radiol 32(10):6628–6636. https://doi.org/10.1007/s00330-022-08989-9

Article  CAS  PubMed  Google Scholar 

Li X, Liang D, Meng J, Zhou J, Chen Z, Huang S, Lu B, Qiu Y, Baker ME, Ye Z, Cao Q, Wang M, Yuan C, Chen Z, Feng S, Zhang Y, Iacucci M, Ghosh S, Rieder F, Sun C, Chen M, Li Z, Mao R, Huang B, Feng ST (2021) Development and validation of a novel computed-tomography enterography radiomic approach for characterization of intestinal fibrosis in Crohn’s disease. Gastroenterology 160(7):2303–2316. https://doi.org/10.1053/j.gastro.2021.02.027

Article  PubMed  Google Scholar 

Cruz-Jentoft AJ, Sayer AA (2019) Sarcopenia. Lancet 393(10191):2636–2646. https://doi.org/10.1016/S0140-6736(19)31138-9

Article  PubMed  Google Scholar 

Ryan E, McNicholas D, Creavin B, Kelly ME, Walsh T, Beddy D (2019) Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 25(1):67–73. https://doi.org/10.1093/ibd/izy212

Article  PubMed  Google Scholar 

Grillot J, D’Engremont C, Parmentier AL, Lakkis Z, Piton G, Cazaux D, Gay C, De Billy M, Koch S, Borot S, Vuitton L (2020) Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn’s disease. Clin Nutr 39(10):3024–3030. https://doi.org/10.1016/j.clnu.2020.01.001

Article  PubMed  Google Scholar 

Adams DW, Gurwara S, Silver HJ, Horst SN, Beaulieu DB, Schwartz DA, Seidner DL (2017) Sarcopenia is common in overweight patients with inflammatory bowel disease and may predict need for surgery. Inflamm Bowel Dis 23(7):1182–1186. https://doi.org/10.1097/MIB.0000000000001128

Article  PubMed  Google Scholar 

Holt DQ, Varma P, Strauss BJG, Rajadurai AS, Moore GT (2017) Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis. Eur J Clin Nutr 71(6):773–777. https://doi.org/10.1038/ejcn.2017.10

Article  CAS  PubMed  Google Scholar 

Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, Burisch J, Castiglione F, Eliakim R, Ellul P, Gonzalez-Lama Y, Gordon H, Halligan S, Katsanos K, Kopylov U, Kotze PG, Krustins E, Laghi A, Limdi JK, Rieder F, Rimola J, Taylor SA, Tolan D, van Rheenen P, Verstockt B, Stoker J, European CS, Colitis O, Abdominal R (2019) ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13(2):144–164. https://doi.org/10.1093/ecco-jcc/jjy113

Article  PubMed  Google Scholar 

Campbell JP, Teigen L, Manski S, Blumhof B, Guglielmo FF, Shivashankar R, Shmidt E (2022) Sarcopenia is more prevalent among inflammatory bowel disease patients undergoing surgery and predicts progression to surgery among medically treated patients. Inflamm Bowel Dis 28(12):1844–1850. https://doi.org/10.1093/ibd/izac013

Article  PubMed  Google Scholar 

Montano-Loza AJ, Mazurak VC, Ebadi M, Meza-Junco J, Sawyer MB, Baracos VE, Kneteman N (2018) Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant. Hepatology 67(3):914–923. https://doi.org/10.1002/hep.29578

Article  PubMed  Google Scholar 

Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, B